share_log

Recursion Pharmaceuticals | 8-K: Current report

SEC ·  Jan 13 14:07

Summary by Futu AI

Recursion Pharmaceuticals announced the release of an updated investor presentation on January 13, 2025, to be presented at the JP Morgan Healthcare Conference. The company showcased its robust pipeline of 10 clinical and pre-clinical programs across oncology, rare diseases, and other high-unmet need areas.The presentation highlighted significant partnership achievements, including four large pharma collaborations that have earned approximately $450M in upfront and milestone payments to date, with potential for over $20B in additional milestone payments. The company's portfolio includes ~10 clinical program milestones expected over the next 18 months.Recursion's unified Operating System (OS) demonstrates both first and best-in-class capabilities, supporting approximately 10 additional advanced discovery programs and over 10 partnered programs. The company's focus spans oncology, immunology, and other areas of high unmet medical need.
Recursion Pharmaceuticals announced the release of an updated investor presentation on January 13, 2025, to be presented at the JP Morgan Healthcare Conference. The company showcased its robust pipeline of 10 clinical and pre-clinical programs across oncology, rare diseases, and other high-unmet need areas.The presentation highlighted significant partnership achievements, including four large pharma collaborations that have earned approximately $450M in upfront and milestone payments to date, with potential for over $20B in additional milestone payments. The company's portfolio includes ~10 clinical program milestones expected over the next 18 months.Recursion's unified Operating System (OS) demonstrates both first and best-in-class capabilities, supporting approximately 10 additional advanced discovery programs and over 10 partnered programs. The company's focus spans oncology, immunology, and other areas of high unmet medical need.

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 1676

Recommended